Please use this identifier to cite or link to this item:
Title: Belinostat and panobinostat (HDACI): In vitro and in vivo studies in thyroid cancer
Authors: Chan, D.
Zheng, Y.
Tyner, J.W.
Chng, W.J.
Chien, W.W. 
Gery, S.
Leong, G.
Braunstein, G.D.
Koeffler, H.P.
Keywords: Histone deacetylases
Novel therapeutic approach
Thyroid cancer
Tyrosine kinase inhibitors
Issue Date: Sep-2013
Citation: Chan, D., Zheng, Y., Tyner, J.W., Chng, W.J., Chien, W.W., Gery, S., Leong, G., Braunstein, G.D., Koeffler, H.P. (2013-09). Belinostat and panobinostat (HDACI): In vitro and in vivo studies in thyroid cancer. Journal of Cancer Research and Clinical Oncology 139 (9) : 1507-1514. ScholarBank@NUS Repository.
Abstract: Purpose: Advanced thyroid cancer responds poorly to most therapies. New therapies and combinations are needed. The aim of this study was to examine both in vitro and in vivo activity of two relatively new histone deacetylase inhibitors (HDACIs), belinostat and panobinostat, and a variety of tyrosine kinase inhibitors (TKIs) against a panel of nine human thyroid cancer cell lines. Methods: The anti-proliferative activity and the effects of HDACIs, TKIs and their combinations on thyroid cancer cells were determined by cytotoxicity assays, microarray and immunoblot analyses. Synergism between HDACIs and TKIs was assessed by the median effects model of Chou-Talalay (Calcusyn ®). Results: Belinostat and panobinostat were active against the thyroid cancer cell lines irrespective of their mutational composition, and belinostat was effective in preventing growth of human thyroid cancer xenografts in immunodeficient mice. Further studies showed that both HDACIs induced apoptosis. HDACI also elevated acetylated histone 3, p21Waf, and PARP, and decreased levels of phosphorylated ERK and AKT (Ser473). RNA assay analysis suggested both HDACIs modulated genes associated with the cell cycle, DNA damage and apoptosis. Most of the TKI (pazopanib, motesanib, sorafenib and dasatinib) were either inactive in vitro or were active only at high doses. However, the novel combinations of either pazopanib or dasatinib TKIs with either belinostat or panobinostat synergistically inhibited cell growth of thyroid cancer cells in vitro. Conclusions: In summary, these HDACIs either alone or combined with selected TKIs may have a role in treatment of aggressive thyroid cancer. © 2013 The Author(s).
Source Title: Journal of Cancer Research and Clinical Oncology
ISSN: 01715216
DOI: 10.1007/s00432-013-1465-6
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.


checked on Dec 12, 2018


checked on Dec 12, 2018

Page view(s)

checked on Dec 14, 2018

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.